Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Gifford

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Bioconjugate Chemistry|June 30, 2020
Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in BloodHanmant Gaikwad, Yue Li, Geoffrey Gifford, et al.
Molecular Pharmaceutics|May 16, 2019
Evaluation of Targeting Efficiency of Joints with Anticollagen II AntibodiesLaren A Lofchy, Vivian P Vu, Nirmal K Banda, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 12, 2019
Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55Geoffrey Gifford, Vivian P Vu, Nirmal K Banda, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Bioconjugate Chemistry|June 30, 2020
Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in BloodHanmant Gaikwad, Yue Li, Geoffrey Gifford, et al.
Molecular Pharmaceutics|May 16, 2019
Evaluation of Targeting Efficiency of Joints with Anticollagen II AntibodiesLaren A Lofchy, Vivian P Vu, Nirmal K Banda, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 12, 2019
Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55Geoffrey Gifford, Vivian P Vu, Nirmal K Banda, et al.
Pageof 1